Another study has revealed that administering a low dose of IL-2 per day selectively activates and expands Tregs in patients with systemic sclerosis (SSc) without activating Teffs, paving the groundwork for a Phase II efficacy trial (NCT01988506) (78). This evidence concerns the gene IL2 and systemic sclerosis.